TABLE 5.

Table of adverse events attributed as related to study drug during prophylactic phase in the safety populationa

Adverse eventNo. (%) of patients in treatment group
Tafenoquine (n = 492)Mefloquine (n = 162)
At least one AE66 (13.4)19 (11.7)
Nausea14 (2.8)4 (2.5)
Vertigo10 (2.0)2 (1.2)
Diarrhea9 (1.8)3 (1.9)
Abdominal pain7 (1.4)2 (1.2)
Abnormal dreaming6 (1.2)1 (0.6)
Somnolence6 (1.2)1 (0.6)
Headache3 (0.6)2 (1.2)
Insomnia3 (0.6)2 (1.2)
  • a Events occurring in >1% of subjects are shown. AE, adverse event.